• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

10.34 -0.93 (-8.25%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 831,759
Open 11.16
Bid (Size) 10.00 (200)
Ask (Size) 10.90 (200)
Prev. Close 11.27
Today's Range 10.25 - 11.57
52wk Range 5.500 - 24.17
Shares Outstanding 26,562,951
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform ↗
September 24, 2026
Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to... 
Via MarketBeat
News headline image
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
September 23, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire

Performance

52-Week Range 57.2% below 52-week high
10.34
5.5052W Low 24.1752W High
1 Week 24.8% below 1-week high
10.251W Low 13.751W High

Arcturus Therapeutics Holdings Inc (ARCT) traded between $5.50 and $24.17 over the past 52 weeks and last traded at $10.34, 57.2% below its 52-week high. Over the past week it ranged between $10.25 and $13.75.

Past 12 Months
-18.0%
-38.9%
+73.2%
+16.2%
+65.4%
-50.0%
1W -$2.27
1M -$6.59
3M +$4.37
6M +$1.44
YTD +$4.09
1Y -$10.32

ARCT was -50.0% over the past year, +16.2% over six months, +65.4% year to date, -18.0% in the last week.

12 Months vs Market
ARCT
-50.0%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months ARCT returned -50.0% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.88× 3-mo avg
Today 831,759 3-mo avg 942.4K
1W
559.5K
1M
790.7K
3M
942.4K
6M
702.9K
YTD
625.7K
1Y
774.6K

ARCT most recently traded 831,759 shares against a 3-month average daily volume of 942.4K.

More News

Read More
News headline image
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
September 18, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
August 31, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances ↗
May 07, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
August 19, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
August 19, 2026
Via Chartmill
News headline image
Arcturus (ARCT) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
News headline image
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline ↗
August 11, 2026
Via MarketBeat
News headline image
Arcturus Therapeutics Q2 Earnings Call Highlights ↗
August 06, 2026
Via MarketBeat
Topics Earnings
News headline image
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
August 06, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
July 28, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
July 20, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Thursday's session: gap up and gap down stocks ↗
July 02, 2026
Via Chartmill
News headline image
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
July 02, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies ↗
June 05, 2026
Via MarketBeat
News headline image
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
May 26, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus (ARCT) Q1 2026 Earnings Call Transcript ↗
May 08, 2026
Via The Motley Fool
Topics Earnings
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
May 07, 2026
Via Chartmill
News headline image
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
May 07, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
April 27, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
April 20, 2026
Via Investor Brand Network
Topics Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
Via Investor Brand Network
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
March 25, 2026
Via The Motley Fool

Frequently Asked Questions

Is Arcturus Therapeutics Holdings Inc publicly traded?
Yes, Arcturus Therapeutics Holdings Inc is publicly traded.
What exchange does Arcturus Therapeutics Holdings Inc trade on?
Arcturus Therapeutics Holdings Inc trades on the Nasdaq Stock Market
What is the ticker symbol for Arcturus Therapeutics Holdings Inc?
The ticker symbol for Arcturus Therapeutics Holdings Inc is ARCT on the Nasdaq Stock Market
What is the current price of Arcturus Therapeutics Holdings Inc?
The current price of Arcturus Therapeutics Holdings Inc is 10.34
When was Arcturus Therapeutics Holdings Inc last traded?
The last trade of Arcturus Therapeutics Holdings Inc was at 10/16/26 04:00 PM ET
What is the market capitalization of Arcturus Therapeutics Holdings Inc?
The market capitalization of Arcturus Therapeutics Holdings Inc is 274.66M
How many shares of Arcturus Therapeutics Holdings Inc are outstanding?
Arcturus Therapeutics Holdings Inc has 275M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap